The findings from the AlphaLISA revealed that patients diagnosed with acute ischemic stroke (AIS), diabetes mellitus (DM), CVD, obstructive sleep apnea syndrome (OSAS), chronic kidney disease (CKD), and various solid malignancies—including esophageal, gastric, colon, lung, and breast cancers—exhibited markedly elevated serum antibody levels directed against the recombinant KIAA0513 protein compared to healthy control subjects. This evidence concerns the gene KIAA0513 and chronic kidney disease.